Aurora Cannabis (ACB) has expanded their IndiMed brand with the launch of IndiMed TEMPO 22, with new 22% THC potency, available through the company’s subsidiary, MedReleaf Australia. IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis to Discuss Fiscal Year 2025 Results in Upcoming Investor Call
- Aurora Cannabis Announces Virtual Annual Meeting for August 2025
- Rubicon Organics appoints Glen Ibott as interim CFO
- Aurora Cannabis introduces its first inhalable resin cartridges in the U.K.
- Aurora Cannabis management to meet virtually with Roth MKM